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1 List of Abbreviations 
ATM    Ataxia telangiectasia mutated    
ATP    Adenosine triphosphate 
ATR    Ataxia telangiectasia and Rad3-related  
BSA    Bovine serum albumine 
CDK    Cyclin-dependent kinase 
DAPI    4',6-diamidino-2-phenylindole   
DDR    DNA double strand repair 
DDT    1,4-Dithiothreitol 
DNA-PK   DNA-dependent protein kinase 
DMSO    Dimethyl sulfoxide 
EDTA    Ethylene diamine tetraacetic acid 
p42/44 Erk 1/2  Mitogen-activated protein kinase with 42 or 44 kDa 
Fapy Ade   4,6-diamino-5-formamidopyrimidine 
FapyGua   2,6-diamino-4hydroxy-5-formamidopyrimidine 
FCS     Fetal calf serum 
Fpg    Formamido pyrimidine glycosylase  
HRP    Horseradish peroxidase 
HRR    Homologous recombination repair 
Kb    Kilo bases 
kDa    Kilodalton 
kDNA    Kinetoplast DNA 
MAPK    Mitogen-activated protein kinase  
Mek1    Meiosis-specific serine/threonine protein 
MIC    Minimal inhibition concentration 
MMPs    Matrix metalloproteinases 
Mre11    Nuclease 
Nbs1 DNA damage repair protein, named after Nijmegen breakage 
syndrome 
NFκB Latent gene regulatory protein activated by various intracellular 
signaling pathways 
NHEJ    Nonhomologous end joining 
PI3K    Phosphatidylinositol-3-kinase 
ROS    Reactive oxygen species 
RT    Room temperature 
Ser    Serine 
TNF    Tumour necrosis factor 
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2 Introduction 
Within the last decade there has been a growing interest in the study of the therapeutic 
potential of natural products. A variety of compounds have been isolated and tested in 
clinical trials. One of these compounds is resveratrol, which is the focus in over 4000 
publications (stand October 2011, PubMed). Resveratrol, amongst others, has shown to 
exhibit beneficial effects in the prevention of different stages of carcinogenesis. 
Much effort is observed concerning the improvement of the biological activity of resveratrol. 
One of these efforts is the development and commercialization of the grapevine shoot extract 
vineatrol®30. Vineatrol®30 contains not only a high amount of resveratrol but also resveratrol 
oligomers and –polymers. Since the extract was admitted as a dietary supplement, it is 
essential to understand the mechanisms underlying the possible anti-cancer potential of 
vineatrol®30 and its constituents.  
In terms of cancer treatment, human topoisomerase II has become a central approach in the 
current research. These essential enzymes control the topology of DNA by creating transient 
breaks in the sugar-phosphate backbone of the double helix. The most effective 
topoisomerase II-targeting drugs induce enzyme-mediated DNA-damage by the generation 
of permanent instead of transient DNA double strand breaks. This effect is called 
topoisomerase-poisoning. A recent study showed that resveratrol inhibits human 
topoisomerase II and induces DNA double strand breaks (Leone et al., 2010). Therefore, the 
effect of resveratrol on topoisomerase II as well as its potential in the induction of DNA strand 
breaks must be confirmed.  
In the current project, it must be determined whether the extract vineatrol®30 acts as an 
inhibitor of the catalytic activity of human topoisomerase II, or as a poison. Furthermore, the 
bioactive constituents of vineatrol®30 concerning the inhibition of human topoisomerase II 
must be identified. Furthermore, it must also be determined whether these substances are 
more effective than the reference substance resveratrol.  
Tumours containing higher levels of topoisomerase II provide potential for targeted and 
improved cancer treatment. For an efficient cancer therapy it is important to understand the 
underlying enzyme-drug-interaction. If the compound is capable of poisoning human 
topoisomerase II, it could be a potential candidate for the application in cancer 
chemotherapy. In the case of a catalytic inhibition, the substance can overcome the DNA 
damaging effect of topoisomerase II poisons.  
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3 Theoretical background 
3.1 Human topoisomerases 
3.1.1 General features  
DNA topoisomerases control and influence the topology of DNA within the cell. These 
essential enzymes maintain the double helical organization of DNA and the circular 
chromosome shape (Champoux, 2001). 
Usually, DNA is negatively supercoiled. This underwound state facilitates strand separation 
as well as initiation, elongation of replication and transcription. During the processes of 
transcription and replication, massive alterations of DNA topology occur. Due to the activity 
of the replication fork, positive supercoiling (overwinding) is induced, which cannot be 
unwound by helicases (Figure 1). Consequently, positive supercoils result in a replication or 
transcription stop and generally lead to suppression of other cellular processes. Moreover, 
nuclear processes influence the genetic material by creating knots and tangles. This 
topological alteration will prevent DNA tracking systems from the separation of the strands. 
Tangles in chromosomes disturb the initial de-condensation in the cell division leading to cell 
death (McClendon and Osheroff, 2007). 
 
Figure 1: Generation of oppositely supercoiled domains by transcription. The transcription machinery 
(R) is shown as a rod. It includes RNA polymerase and assistant proteins as well as nascent RNA with 
associated proteins (Wang, 2002). 
Consequently, in processes where the strands have to be separated such as replication, 
transcription or recombination, topological alterations have to occur (Wang, 1996). 
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Topoisomerases are responsible for unwinding of tangles or knots in double stranded DNA 
(McClendon and Osheroff, 2007). Before cytokinesis can proceed, catenated DNA resulting 
from replication has to be unlinked by topoisomerases (Pommier et al., 2010). These 
enzymes are also involved in recombination, separation, condensation as well as de-
condensation of chromosomes (McClendon and Osheroff, 2007). 
Taken together, topoisomerases solve the structure-related problems and optimize the 
function of DNA by the fine-tuning of the topological state (Wang, 1996). For that purpose, 
topoisomerases are able to create transient breaks in the sugar-phosphate backbone of the 
double helix (McClendon and Osheroff, 2007).  
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3.1.2 Classification  
Topoisomerases are classified according to their cleavage mechanism. If they induce 
cleavage of one DNA strand, they are defined as type I enzymes. If they induce DNA double 
strand breaks, they are defined as type II topoisomerases (Sng et al., 1999). 
Type I topoisomerases pass one strand of DNA through a break in the opposite strand or 
perform a controlled rotation about the break. These enzymes eliminate superhelical twists 
and decrease torsional tension in double stranded DNA. When tracking systems lead to 
topological alterations, this class of topoisomerases plays an important role maintaining 
genomic integrity (McClendon and Osheroff, 2007) (Figure 2a). 
Type II topoisomerases catalyse the ATP-dependent transfer of a DNA duplex strand 
through a double-stranded gap (Champoux, 2001) (Figure 2b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: a) Type I topoisomerase recognize partially unwound segments of DNA and pass one 
strand through a break made in the other b) Type II topoisomerases can pass a duplex DNA through a 
DNA double strand break in another duplex (Lewin, 2008). 
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Type A subfamily members generate a protein link to 5´ phosphate and type B 
topoisomerases bind to 3´ phosphate on DNA (Sng et al., 1999). Selected subfamilies of 
topoisomerases are shown in table 1. 
Subfamily Representative members 
IA Mammalian DNA topoisomerase IIIα und IIIβ 
IB Eukaryotic DNA topoisomerase I 
IIA  Bacterial gyrase 
  Yeast DNA topoisomerase II  
  Drosophila DNA topoisomerase II  
  Mammalian DNA topoisomerase IIα und IIβ 
IIB Sulfolobus shibatae  DNA topoisomerase VI 
 
Table 1: Subfamilies of DNA topoisomerases. Mammalian topoisomerase IIα and IIβ are highlighted 
as these enzymes were used in the experiments described later in chapter 5 (modified according to 
Wang, 2002). 
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3.1.3 Topoisomerase II 
3.1.3.1 Catalytic cycle of topoisomerase II 
The mechanism catalyzed by the homodimeric protein topoisomerase II is based on a DNA 
double-strand passage reaction. After binding two distinct duplexes of DNA, it cleaves one of 
the segments, the G (gate) segment, and passage the second segment, the T (transported) 
segment, through the nucleic acid gate. The enzyme ligates the DNA strand break and 
passes the trans-located segment through a gate in the protein (Figure 6). With closing the 
protein gate, a new catalytic cycle can be started (Fortune et al., 1999).  The energy for the 
translocation of one DNA double strand through the other is provided by ATP (Osheroff et al., 
1983). In total, topoisomerase II requires two molecules of ATP (Lindsley and Wang, 1991). 
In detail, the catalytic cycle of topoisomerase II can be divided into six steps summarized in 
figure 4: 
Step 1: DNA binding 
The initial interaction of DNA and topoisomerase II occurs without the presence of any 
cofactors. However, the association rate is stimulated by divalent cations (Osheroff, 1987). 
Although no characteristic features of DNA recognition sequences are recognizable, the 
enzyme prefers binding to bent DNA (Bechert et al., 1994). The rate of topoisomerase II 
binding and catalytic activity depends on the topology of the DNA substrate as the enzyme 
prefers binding to negatively or positively supercoiled over relaxed molecules (Osheroff, 
1986). The reason for the differentiation of the enzyme between the topological states of 
DNA lies in the recognition of DNA crossovers or nodes. Intramolecular crossovers are found 
in supercoiled DNA substrates, whereas intermolecular crossovers are observed in 
catenated molecules (Zechiedrich and Osheroff, 1990; Roca et al., 1993). 
Step 2: pre-strand passage DNA cleavage/re-ligation 
The presence of a divalent cation leads to an equilibrium between cleavage and re-ligation of 
the G segment before strand passaging occurs (Osheroff, 1987). DNA double strand breaks 
are generated because topoisomerase II nicks each of the opposite strands of the double 
helix leading to two 5`-overhangs with the lengths of 4 bp (Sander and Hsieh, 1983). The 
cleavage reaction implies the interaction between a specific tyrosine residue of each enzyme 
monomer and the simultaneously generated 5´end of the broken double strand, resulting in a 
transient phosphodiester bond (Pommier et al., 2010). The DNA cleavage intermediate is 
shown in figure 4 in brackets. 
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Mechanistically, the cleavage reaction functions as a trans-esterification induced by the 
active tyrosine of the enzyme which performs a nucleophilic attack to the phosphate end of 
the simultaneously generated DNA break. Consequently, a transient covalent complex 
between the protein and DNA is generated. The reaction is reversible by the re-ligation of the 
DNA backbone bond and the release of the tyrosine residue (Wang, 2002) (Figure 3). 
 
Figure 3: Catalysis of transient breakage of DNA by DNA topoisomerases (Wang, 2002). 
 
Step 3: strand passage 
With the binding of ATP as cofactor the clamp conformation of the enzyme is converted from 
an open to a closed form. This conformational change triggers DNA double strand passage 
(Pommier et al., 2010). The energy for the strand passage reaction is taken from the 
triphosphate portion of the high energy cofactor (Osheroff et al., 1983). 
Step 4: post-strand passage DNA cleavage/re-ligation 
As before the translocation, the DNA cleavage of the G segment is compensated by the re-
ligation. Compared to the complex that is generated before ATP binding, the enzyme-DNA 
complex shows a 2-4-fold higher stability with the energy of the cofactor (Robinson and 
Osheroff, 1991). 
Step 5: ATP hydrolysis 
By performing ATP hydrolysis, the protein clamp of the enzyme is opened in order to release 
the G segment. Topoisomerase II does not essentially require DNA binding for ATP 
hydrolysis (Osheroff, 1986). 
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Step 6: enzyme recycling 
Topoisomerase II can start a new round of catalysis, either on the same DNA substrate 
remaining associated or on another DNA double strand dissociating from the former 
substrate (Osheroff et al., 1983). 
 
Figure 4: The catalytic cycle of topoisomerase II. The individual steps of the catalytic cycle are shown. 
(1) DNA binding of the enzyme; (2) pre-strand passage cleavage/re-ligation; (3) DNA strand passage; 
(4) post-strand passage cleavage/re-ligation (5) ATP hydrolysis (6) enzyme recycling. Brackets 
indicate that the enzyme-DNA-complex is a short-lived intermediate (Burden and Osheroff, 1998). 
As mentioned before, there are specific sites of enzyme-mediated-DNA cleavage within its 
binding/recognition sites (Spitzner and Muller, 1988). These recognition sites are conserved 
(Muller et al., 1988). Therefore, any topoisomerase II can be used to obtain a reproducible 
characteristic pattern of cleavage sites on a DNA molecule (Burden and Osheroff, 1998). 
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The formation of covalent DNA/topoisomerase II-intermediates is a critical step in the cell. 
Therefore, the concentration of these transient enzyme/DNA-complexes is tightly regulated. 
(Wilstermann and Osheroff, 2003). The topoisomerase II-associated DNA double strand 
breaks are transient under normal cellular conditions, as intermediates during the catalytic 
cycle of the enzyme (Osheroff et al., 1991). The DNA double strand breaks occur in low 
steady-state-levels which are tolerated by the cell (Kohn, 1996).  If the activity of 
topoisomerase is reduced, the chromosomes could not be separated resulting in impaired 
mitosis and cell death (Wilstermann and Osheroff, 2003). If the level or the lifetime of the 
transient enzyme/DNA-intermediates is increased, DNA aberrations will occur (Corbett and 
Osheroff, 1993).  
The transient enzyme/DNA-complex can lead to permanent DNA double strand breaks if 
polymerases or helicases pass the interaction site and disrupt the complex (Wilstermann and 
Osheroff, 2003). Consequently, these double strand breaks are no longer surrounded by the 
two monomers of topoisomerase II and repair pathways are activated.  
With positive supercoiled DNA, the level of covalent topoisomerase II/DNA-intermediates is 
reduced 2-to 4-fold. Therefore, the probability of a permanent strand breaks decreases as a 
collision with a tracking system is less likely to occur (McClendon and Osheroff, 2007). With 
this substrate, topoisomerase II becomes a safer tool in DNA processes on the one hand, but 
the lethal effect of topoisomerase II-targeting-anti-cancer drugs is reduced on the other hand 
(McClendon and Osheroff, 2007). 
 
 
  
10 
 
3.1.3.2 Isoforms and structure 
In vertebrates two isoforms of topoisomerases II are expressed, IIα and IIβ. Although the 
isoenzymes differ in their molecular mass (170 and 180 kDa, respectively) and are encoded 
by different genes, they show high amino acid conformity. However, topoisomerases IIα and 
IIβ are expressed differently and are involved in distinct processes (Velez-Cruz and Osheroff, 
2004). 
Topoisomerase IIα plays an important role during cell proliferation and is essential for active 
cell growth. Topoisomerase IIα levels depend on the proliferative state of the cell and show 
the highest rate in G2/M phase. As this isoform is associated with the chromosomes and 
located at replication forks during mitosis (Woessner et al., 1991), it is mostly involved in 
DNA replication and chromosome segregation (Wang, 2002). Furthermore, it was shown that 
the enzyme relaxes positive DNA supercoils 10-fold faster in comparison to negative 
supercoils (Corbett et al., 2004). 
In contrast to topoisomerase IIα, the IIβ isoform is not involved in cell proliferation as it 
dissociates from the chromosomes during mitosis. Therefore, topoisomerase IIβ is not able 
to overcome a loss of the IIα isoform (Austin and Marsh, 1998). As the levels of this isoform 
are independent of the cell cycle, it might be responsible for the housekeeping functions of 
topoisomerase II (Heck et al., 1988). Topoisomerase IIβ shows the same activity with 
negative and positive supercoils as this isoform is not involved in replication (McClendon et 
al., 2005). 
The two topoisomerase II isoenzymes show similarities in their primary structure. The N-
terminal domain (first 670 amino acids) contains the site of ATP binding/hydrolysis, whereas 
the central domain (amino acids 671-1200) contains the active tyrosine (Y805) (Velez-Cruz 
and Osheroff, 2004). 
In contrast to the other domains, the C-terminal domain shows high variability among the 
species and between the human isoforms. It is not only responsible for catalytic activity 
in vitro but also for nuclear localization and contains phosphorylation-sensitive sites (Shiozaki 
and Yanagida, 1992).The C-terminal domain is essential in recognizing the geometry of DNA 
(Corbett et al., 2004). Figure 5 shows the linear organisation of human topoisomerase IIβ. 
 
Figure 5: Linear domain organisation of human topoisomerase IIβ (Wu et al., 2011).  
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3.1.4 Classification of topoisomerase II inhibitors 
Topoisomerase II-targeting drugs can be divided into two classes. The first class contains 
agents stabilizing the enzyme/DNA-intermediate by the generation of a ternary complex. 
These compounds are clinically used and include e.g. etoposide, doxorubicin and 
mitoxantrone. Due to the stabilization of the protein/DNA-complex during the cleavage 
process, these agents are called topoisomerase poisons. The second class of 
topoisomerase II-targeting compounds inhibits the catalytic activity of the enzyme prior to 
DNA binding. Cell death is a possible consequence as the enzyme loses its essential activity. 
The agents are therefore called catalytic inhibitors. There are different steps in the enzyme 
cycle which can be affected by topoisomerase poisons or inhibitors. Figure 6 summarizes the 
effects of catalytic inhibitors and topoisomerase II poisons that are described in the following 
chapter 3.1.4.1. A competitive inhibition of ATP binding prevents the strand passage 
reaction. The inhibitor aclarubicin impairs the protein/DNA-binding and prevents the cleavage 
reaction. A suppression of the cleavage reaction per se is also possible as observed with the 
inhibitor merbarone. Apart from the cleavage, the re-ligation step can also be impaired. The 
topoisomerase II poison etoposide e.g. stops the catalytic cycle between DNA cleavage and 
re-ligation. Consequently, the enzyme recycling is blocked and further catalytic cycles cannot 
occur (Nitiss, 2009).  
 
Figure 6: The catalytic cycle of DNA topoisomerase II (modified according to Larsen et al., 2003). 
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3.1.4.1 Catalytic inhibitors 
Inhibitors impair the catalytic activity of topoisomerase II by preventing the formation of 
transient enzyme/DNA-intermediates. Aclarubicin e.g. prevents the binding of topoisomerase 
II to DNA by intercalation (Sorensen et al., 1992). Coumarin drugs, e.g. novobiocin, inhibit 
the catalytic activity of topoisomerase II by blocking the ATP binding site (Gormley et al., 
1996). By contrast, merbarone inhibits enzyme-mediated DNA cleavage with no influence on 
DNA-binding or ATP hydrolysis (Fortune and Osheroff, 1998). 
Furthermore, oligomeric procyanins were shown to inhibit the catalytic activity of human 
topoisomerase IIβ (Fridrich et al., 2007).The anthocyanidin delphinidin acts as a catalytic 
inhibitor of topoisomerase IIα without stabilizing the enzyme/DNA-intermediate (Esselen et 
al., 2009). Also cyanidin was found to inhibit the catalytic activity of topoisomerase II without 
preferred interaction with one of the two isoenzymes (Habermeyer et al., 2005). 
Bisdioxopiperazines, like dexrazoxane (IRF-187), are classified as catalytic inhibitors 
although they stabilize the enzyme/DNA-association like topoisomerase-poisons (Roca et al., 
1994). As these compounds are highly specific for the enzyme, they are the most frequently 
used catalytic inhibitors of topoisomerase II in mammalian cells (Andoh and Ishida, 1998). 
Apart from their chelating activity, they block the catalytic cycle of topoisomerase II between 
strand passage and hydrolysis of the second ATP. Therefore, the enzyme is inhibited when it 
is associated to the cleaved DNA double strand (Andoh and Ishida, 1998). Except from 
bisdioxopiperazines, catalytic inhibitors show no specificity to topoisomerase II (Nitiss, 2009). 
It is a common feature of catalytic inhibitors that they overcome the toxic effect of 
topoisomerase poisons. Therefore, it can be concluded that catalytic inhibitors and 
topoisomerase poisons differ completely in their mechanism of action (Jensen and Sehested, 
1997). A recent study of our group showed that the anthocyanin cyanidin-3-glucoside (C3G) 
acts as an antagonist of camtothecin or doxorubicin. The compound impairs the poison-
induced stability of the enzyme/DNA-intermediate (Esselen et al., 2011). Furthermore, it was 
shown in HT29 cells that delphinidin decreases the level of ternary topoisomerase IIα/DNA- 
complexes with etoposide and doxorubicin (Esselen et al., 2009). The catalytic inhibitor 
suramin prevents the enzyme/DNA-interaction (Bojanowski et al., 1992) and also inhibits the 
generation of ternary topoisomerase II/DNA/drug-complexes with the poison amasacrine 
(Lelievre et al., 1995). 
The structures of selected catalytic inhibitors are summarized in figure 7. 
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Figure 7: Catalytic inhibitors of topoisomerase II (modified according to Larsen et al., 2003). 
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3.1.4.2 Topoisomerase II poisons 
Compounds increasing the level of DNA/topoisomerase II-intermediates by creating a ternary 
complex are classified as topoisomerase poisons. By the formation of permanent instead 
of transient DNA double strand breaks, topoisomerase II might be shifted from an essential 
enzyme to a potent cytotoxic tool (Wilstermann and Osheroff, 2003).     
Severe consequences occur with the increase in covalent enzyme/DNA-complexes. In 
addition to DNA damage, the transcription and replication machinery is disturbed by 
topoisomerase II poisons (Nitiss, 2009). 
Generally, topoisomerase II poisons can act via two mechanisms. Some compounds prevent 
the enzyme from the re-ligation of the cleaved DNA segment and increase the lifetime of the 
covalent DNA/topoisomerase II-intermediates. Such poisons are e.g. etoposide, teniposide 
and the DNA intercalators doxorubicin and amasacrine. Another mechanism of action is the 
up-regulation of covalent enzyme/DNA-complex formation as performed e.g. by the natural 
flavonoid genistein. It is also possible to impair the DNA binding/dissociation equilibrium and 
therefore to increase the level of topoisomerase II-mediated cleavage (Fortune and Osheroff, 
2000) (Figure 8). 
 
Figure 8: Effects of drugs on the cleavage/re-ligation equilibrium of topoisomerase II. Cleavage-
enhancing-drugs are shown on the top of the figure, re-ligation-decreasing drugs are depicted on the 
bottom (Burden and Osheroff, 1998). 
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Figure 9: Routes of topoisomerase II/ /DNA/drug-complex formation (Burden and Osheroff, 1998). 
There are three possible routes by which the ternary enzyme/DNA/drug-complex can be 
generated, as shown in figure 9. The first route implies the drug binding to DNA and the 
enzyme binding to this complex. According to the second route, the enzyme binds to DNA 
and the drug associates to the enzyme/DNA-complex. The third route implies the 
enzyme/drug-interaction followed by DNA binding (Burden and Osheroff, 1998) which was 
shown to be the preferred route by many anticancer drugs (Burden et al., 1996). 
Topoisomerase II is reported to be the most important cytotoxic target of anticancer drugs 
although no isoform-specific compounds have been developed (Kaufmann, 1998). Table 2 
summarizes topoisomerase II poisons used in cancer chemotherapy and table 3 illustrates 
investigational topoisomerase II poisons. 
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Table 2:  Clinical use of topoisomerase II poisoning anti-cancer agents (Hande, 1998). 
 
 
 
 
 
 
 
Table 3: Investigational agents which poison topoisomerase II (Hande, 1998). 
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Non-covalent topoisomerase II poisons interact at the interface between the DNA segment 
and the active site of the enzyme. It is supposed that the compounds enter the complex by 
the interaction with topoisomerase II (Leroy et al., 2001). These topoisomerase II poisons are 
used for chemotherapy (McClendon and Osheroff, 2007). The compounds show differences 
in their binding properties. Etoposide, genistein and quinolones such as CP-115.953 are non-
intercalative topoisomerase II poisons (McClendon and Osheroff, 2007). 
Very early, etoposide was found to induce single and double strand breaks in vitro (Loike and 
Horwitz, 1976). Now, etoposide is one of the most commonly used anti-cancer-drugs and is 
applied against lung-cancer, lymphomas or germ-line malignancies (DeVore et al., 1992); 
(Belani et al., 1994). A complication of this kind of cancer treatment is the possibility of 
secondary malignancies resulting from translocations. It was shown that topoisomerase IIβ is 
responsible for etoposide-induced acute myeloid leukaemia (Nitiss, 2009). 
A recent X-ray structure of etoposide in the ternary complex with topoisomerase IIβ is shown 
in figure 10. 
 
Figure 10: Orthogonal views of the ternary topoisomerase IIβ/DNA-complex with etoposide. DNA is 
shown in blue. One enzyme monomer is illustrated in grey, the other follows the scheme shown in 
figure (Wu et al., 2011). 
The etoposide-analogue teniposide shows similar potential in inhibiting topoisomerase II but 
with higher cytotoxicity due to the better cellular uptake (Stahelin and von Wartburg, 1991). 
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DNA intercalation is also possible as shown by amasacrine as well as by doxorubicin and 
mitoxantrone showing a very high DNA affinity (McClendon and Osheroff, 2007). 
Anthracyclins are intercalative topoisomerase II poisons as the planar aglycon moiety can 
insert between base pairs of DNA (Bachur et al., 1992). In clinic, the most frequently used 
anthracyclin is doxorubicin (Goebel et al., 1996). An anthracyclin analogue with an improved 
tolerability profile is e.g. the anthracenedione mitoxantrone (Faulds et al., 1991). 
With non-intercalative drugs, the rate of the ternary complex formation with enzyme/DNA is 
not influenced by the DNA substrate (McClendon, Osheroff, 2007). By contrast, intercalative 
drugs show a “bell-shaped” curve in the ternary complex with negatively supercoiled DNA 
substrates (McClendon, Osheroff, 2007) and the cleavage rate decreases with higher drug 
concentrations. With positively supercoiled DNA, the cleavage rate remains high 
(McClendon, Osheroff, 2006).  
Bioflavonoids play an important role as phytoestrogens and are contained in many 
vegetables, fruits, legumes and plant leaves (Kurzer and Xu, 1997). Genistein contained in 
soy products may play an important role in chemoprevention as shown by the low incidence 
of breast, prostate and colon cancer in the Asian population (Barnes et al., 1995). The 
isoflavone genistein was shown to be the most active topoisomerase poison amongst other 
bioflavonoids, flavones, flavonols and isoflavones acting mainly by inhibiting enzyme-
mediated DNA ligation. Daidzein, myricetin, quercetin, kaempferol and luteolin, for instance, 
were also shown to inhibit both isoenzymes in cultured human cells (Bandele and Osheroff, 
2007). Furthermore, the green tea catechin (-) -epigallocatechin-3-gallate was also found to 
act as topoisomerase II poison (Suzuki et al., 2005). 
The structures of selected non-covalent topoisomerase II poisons are shown in figure 11. 
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Figure 11: Structures of selected non-covalent topoisomerase II poisons (Burden and Osheroff, 
1998). 
Covalent topoisomerase II poisons contain sulfhydryl-reactive compounds e.g. quinones 
(Wang et al., 2001). Interestingly, in the presence of a nucleic acid substrate, quinones act 
as topoisomerase II poisons, whereas in the absence of DNA they inhibit the catalytic activity 
of the enzyme. It was concluded that they might influence the enzyme during the cleavable 
complex formation. This mechanism might be based on the cross-linking of the enzyme´s N-
terminal gate while DNA is enclosed within the active site. The entry of the DNA segment, 
which is not yet captured by the enzyme, is prevented (Bender et al., 2006). Quinones prefer 
the inhibition of topoisomerase IIα (Lindsey et al., 2004). 
Camptothecins are intercalative topoisomerase I poisons as they integrate into the ternary 
complex between the -1 and +1 bases. The drug is associated to the protein by hydrogen 
bonding, which also stabilizes the ternary enzyme/DNA/poison-complex. Furthermore, 
stacking interactions between the compound and the bases are involved in ternary 
enzyme/DNA/drug-complex stabilization. The same mechanism of interfacial inhibition can 
be used to explain the intercalation of topoisomerase II poisons. As poisons alter the 
geometry of DNA, no re-ligation after the strand passage reaction can occur (Nitiss, 2009). 
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However, this is an explanation for topoisomerase II poisons blocking the re-ligation of the 
DNA double strand break and cannot be applied to cleavage stimulation agents (Robinson et 
al., 1991). 
In cells treated with topoisomerase II poisons, the two subunits of the homodimer strongly 
bind to DNA. Therefore, proteolytic or nucleolytic processing might be additionally required to 
induce DNA double strand cleavage. When the collision with a tracking system occurs, the 
ternary enzyme/DNA/drug-complex becomes irreversibly and this problem can only be 
solved by inducing repair or apoptosis. In order to repair the drug-induced DNA damage, the 
ternary topoisomerase II/DNA/drug-complex has to be differentiated from an active enzyme 
that releases DNA within a normal catalytic cycle. Successful repair has to release the 
covalently bound enzyme from the DNA substrate and has to re-ligate the double strand 
break. The recognition mechanism might involve the tracking system, which is prevented 
from performing transcription or replication. A possible repair mechanism is the nucleolytic 
excision of the DNA lesion within the enzyme/DNA-complex (Nitiss, 2009). 
A second possibility to get rid of the enzyme bound to the DNA is the degradation of the 
enzyme by proteolysis. It was shown that topoisomerase IIβ was degraded by ubiquitinilation. 
Therefore, it is supposed that topoisomerase IIβ degradation functions as a signal for drug-
induced DNA damage (Mao et al., 2001). Recently, this mechanism was also observed with 
topoisomerase IIα but the degradation occurs to a lower extent compared to the β isoform 
(Fan et al., 2008). 
Two pathways might be responsible for the processing of the drug-induced DNA damage. On 
the one hand there might exist a transcription-induced pathway with proteasome-mediated 
processing, and on the other hand a replication-dependent pathway with no proteasome 
involvement is supposed (Nitiss, 2009). Both pathways lead to the loss of topoisomerase and 
to the generation of DNA double strand breaks, which might be repaired by a common 
mechanism. Non-homologous end-joining might be such a mechanism, as cells lacking this 
ability react hypersensitive towards topoisomerase II-mediated DNA damage (Nitiss, 2009). 
An excess of permanent double strand breaks can lead to apoptotic cell death (Kaufmann, 
1998). 
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As mentioned before, topoisomerase II is one of the main targets in anticancer therapy. The 
level of topoisomerase II expression shows a direct proportionality to the drug sensitivity 
(Nitiss and Beck, 1996). Therefore, a targeted regulation of topoisomerase II levels can 
induce resistance to a wide range of topoisomerase poisons (Nitiss, 2009).This coherence 
was also proved in vivo (Burgess et al., 2008). 
Both isoenzymes of topoisomerase II show an interaction with poisons but the α isoform is 
the preferred cytotoxic target, as it is highly present in proliferating cells (Sullivan et al., 
1987). 
That means for anticancer therapy that the treatment of tumours with topoisomerase-
targeting drugs might be very efficient if they express a high level of the enzyme (Nitiss, 
2009).  
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3.2 Red wine polyphenols 
3.2.1 General features 
Resveratrol (3, 4`, 5-trihydroxystilbene) is a phytoalexin belonging to the class of stilbene 
compounds. Resveratrol acts both as a natural antibiotic and as a proliferation inhibitor. In 
Vitis vinifera, it is produced during infection and blocks the proliferation in Botrytis cinerea. 
Furthermore, the stilbene is generated in response to environmental stress like climate, 
ozone and UV-radiation (Langcake, 1976 and 1979). 
Resveratrol is synthesised from the precursor phenylalanine catalyzed by the enzyme 
stilbene synthase. The compound is contained in more than 70 plant species out of 32 
genera (Figure 12). Resveratrol and its natural analogues piceatannol and pterostilbene were 
found in peanuts (Arachis spp) and berries (Vaccinium sp). High concentrations are present 
in red wine and grape juice, as one gram of fresh grape skin contains about 50-100 mg of 
resveratrol (Harikumar and Aggarwal, 2008). 
 
Figure 12: Structure and sources of resveratrol (Harikumar and Aggarwal, 2008).  
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The structural features of resveratrol are two phenole rings connected by a styrene double 
bond determining cis or trans conformation, with the trans form as the more stable isomer 
(Harikumar and Aggarwal, 2008). 
As the trans form is converted to the cis isomer upon UV-light exposure, isolation was 
performed in dark conditions (Lin et al., 2007). Protected from light and high pH buffers, 
resveratrol is stable for several months. It shows the highest solubility in ethanol and DMSO 
(Harikumar and Aggarwal, 2008). 
In Mediterranean nutrition, moderate red wine consumption as well as the intake of fruits, 
nuts, vegetables and legumes play an important role. In this context, the term “French 
Paradoxon” was defined, as a lower prevalence of coronary heart disease has been 
observed in the French population, despite their high fat- and cholesterol-rich diet. Several 
studies have confirmed that red wine shows beneficial effects concerning the incidence of 
cardiovascular diseases (Estruch, 2000; Di Castelnuovo et al., 2002). 
Indeed, many in vivo studies have shown that resveratrol treatment is of benefit against a 
variety of age-associated diseases like cancer, diabetes, Alzheimer´s disease, 
cardiovascular and pulmonary diseases. Resveratrol has been demonstrated to be involved 
in a wide range of pathways and interacts with a variety of cell-signaling molecules as 
summarized in figure 13. 
  
Figure 13: Various gene products that are modulated by resveratrol (Harikumar and Aggarwal, 2008). 
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Vineatrol®30 
The grapevine shoot extract vineatrol®30 was developed by the French firm Actichem and 
BRECO GmbH and was brought on the market. The extract was produced by water/ethanol 
extraction from the early sprouts of Vitis vinifera in Bordeaux. Vineatrol®30 contains not only 
a high ratio of resveratrol but also a high portion of resveratrol oligomers and –polymers 
(Table 4). 
Table 4: Resveratrol-oligomers contained in vineatrol
®
30 and the content [%] in the extract. 
 
Resveratrol-oligomers, contained in vineatrol®30, are e.g. the tetramers hopeaphenol (Figure 
14a) and r-2-viniferin (Figure 14b) as well as the dimers ε-viniferin (Figure 14c) and 
ampelopsin A. 
Similar to resveratrol, the oligomers exhibit a variety of health supporting effects. The dimer 
ε-viniferin showed an anti-oxidative (Privat et al., 2002) as well as an anti-inflammatory 
(Zhang et al., 2004) effect. Furthermore, it is anti-carcinogenic (Kim et al., 2002) and 
neuroprotective (Yanez et al., 2006). The tetramer r-2-viniferin showed an anti-oxidative 
effect and in this context a benefit for the cardiovascular system was concluded (Huang et 
al., 2005). Furthermore, it also acts neuroprotective (Jang et al., 2007). 
Resveratrol monomers and oligomers content in vineatrol®30 [%] 
  
ε-viniferin 14,6 
trans-resveratrol 7,7 
ampelopsin A 3,4 
miyabenol C 2,5 
r-viniferin 2,5 
iso-trans-ε-viniferin 2,4 
hopeaphenol 1,8 
r-2-viniferin (visitin A) 1 1,6 
trans-piceatannol 0,6 
total ratio resveratrol-monomers and 
oligomers 
37,1 
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The tetramer hopeaphenol was shown to have an anti-carcinogenic potential (Sahidin et al., 
2005), an anti-inflammatory effect as well as an anti-microbial effect (Zgoda-Pols et al., 
2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14:  Structures of hopeaphenol (a), r2-viniferin (b) and ε-viniferin (c). 
 
The extract was shown to be a free-radical-scavenger and a potent antioxidant at non-
cytotoxic concentrations (Muller et al., 2009). 
  
a
  a 
b 
 
c 
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3.2.2 Influence on DNA integrity 
Resveratrol was shown to induce the histone H2AX phosphorylation. DNA double strand 
breaks might be induced due to a poisoning effect on human topoisomerase IIα (Leone et al., 
2010). This result might indicate an effect of resveratrol in terms DNA double strand break 
induction. 
A previous study (Cho et al., 2000) defined resveratrol as one of the potent chemo-
preventive agents with an effective inhibition of the catalytic activity of mammalian 
topoisomerase II. Resveratrol showed a 50% inhibition of topoisomerase II at a concentration 
of 65.72 µM. Jo et al., 2005, showed a dose-dependent enzyme inhibition with an IC50 at a 
resveratrol concentration of 78.86 µM. 
Resveratrol treatment for four hours resulted in a chromosome displacement and in the 
induction of micronuclei (Schmitt et al., 2002). Furthermore, it was shown that the stilbene 
induced structural chromosome aberrations, particularly chromatid breaks and sister 
chromatid exchange (Matsuoka et al., 2001). Resveratrol treatment resulted in an 
enhancement of nuclear size indicating that apoptotic cell alterations proceed (Delmas et al., 
2003). Concerning DNA integrity, an inter-nucleosomal fragmentation resulting from a 
cleavage in the linker region between nucleosomes was detected, upon resveratrol exposure 
at a range of concentrations between 20-100 µM for 24 hours (Woo et al., 2007). 
Several studies investigated the strand breaking potential of resveratrol in the presence of 
Cu(II) and under oxidative conditions. Mobilization and reduction of endogenous Cu(II) ions 
by resveratrol induces DNA scission via the generation of ROS (Hadi et al., 2010). The 
presence of catalase inhibited the copper-catalyzed DNA cleavage effect of resveratrol 
indicating a requirement of H2O2 in the reaction (Fukuhara and Miyata, 1998). As cancer cells 
were shown to exhibit elevated levels of endogenous copper, this effect implicates the 
possibility of a tumour-cell-specific DNA cleavage (Ebadi and Swanson, 1988). Although 
200 µM of resveratrol promote DNA breakage without the addition of Cu(II) in human 
peripheral lymphocytes, it was shown that intracellular copper ions are involved in the DNA 
breakage reaction (Hadi et al.,  2010). 
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Additionally, in the presence of antioxidants, like ascorbic acid and glutathione, resveratrol 
did not influence the DNA cleavage rate (Burkitt and Duncan, 2000). By contrast, resveratrol 
acts as a scavenger of hydroxyl and superoxide radicals (Leonard et al., 2003). These data 
indicate that resveratrol shows a Janus face concerning oxidative activity, as it can switch 
between an anti-oxidative and a pro-oxidative effect. 
Furthermore, resveratrol was shown to be involved in DNA double strand repair mechanisms 
as it activates ATM and/or ATR (Gatz et al., 2008). This aspect is very important due to the 
phosphorylation of H2AX and will be discussed later in chapter 5.1. 
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4 Aim of the Master´s Project 
Recently, resveratrol was shown to inhibit the catalytic activity of human topoisomerase IIα. 
γH2AX foci were detected indicating a DNA damaging effect of the substance (Leone et al., 
2010).  
Therefore, the first aim of the current study was to confirm the effect of resveratrol on 
topoisomerase IIα and on DNA integrity. By the use of the Comet assay, the DNA strand 
breaking potential of the polyphenol was investigated in the vulva carcinoma cell line A 431. 
Conducting a cell-free Decatenation assay, the potency of resveratrol to inhibit the catalytic 
activity of topoisomerase IIα was examined. 
The second aim was to examine three selected constituents of the extract vineatrol®30, as 
well as the investigation of the extract per se. The grapevine-shoot extract vineatrol®30, in 
particular, contains resveratrol oligomers and polymers. As the extract has been admitted as 
a dietary supplement, it is essential to understand the mechanisms underlying the possible 
anti-cancer potential of vineatrol®30 and its constituents. It was suggested, that resveratrol 
oligomers might be even more effective than the reference substance. Using the 
Decatenation assay we investigated whether the extract, as well as the substances inhibit 
the catalytic activity of human topoisomerase IIα. As the reference substance resveratrol 
showed potent catalytic inhibition of topoisomerase IIα and might induce DNA strand breaks 
(Leone et al., 2010), a poisoning of the enzyme by resveratrol was suggested. Using the 
ICE-bioassay the poisoning effect of the extract vineatrol®30 on topoisomerase II was 
examined in the vulva carcinoma cell line A 431, as these cells showed over-expression of 
human topoisomerase (Meyer et al., 1997). 
By the combination of the Decatenation assay and the ICE-bioassay, it was distinguished 
between catalytic inhibition and topoisomerase II poisoning. Cancer therapy is only effective 
when the underlying enzyme-drug-interaction is understood. Therefore, the anti-cancer 
potential of vineatrol®30 and the three selected constituents must be estimated concerning 
the effect on human topoisomerase II. 
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5 Results and Discussion 
5.1 Effect of resveratrol on DNA integrity 
In order to investigate the strand breaking potential of resveratrol, the Comet assay was 
carried out in the vulva carcinoma cell line A 431. We performed the Comet Assay under 
alkaline conditions according to Singh et al., 1988, to detect both DNA single and double 
strand breaks. During the experimental setup, the cells were treated with formamido 
pyrimidine glycosylase (fpg) to examine the presence of the formamidopyrimidines 4,6-
diamino-5-formamidopyrimidine (FapyAde) and 2,6-diamino-4-hydroxy-5-formamidopyrimi-
dine (FapyGua), major DNA lesions caused by UV radiation, photosensitization or 
H2O2/metal ions (Dizdaroglu et al., 2008). Therefore, these compounds result from oxidative 
induced DNA damage (Dizdaroglu, 1992). As they derive from purines, they can be regarded 
as purines with an opened imidazole ring, although these compounds are pyrimidines. The 
major difference to other pyrimidines is that they are linked to desoxyribose not through N1, 
but through the amino group attached to C6 (Dizdaroglu et al., 2008). Using the repair 
enzyme fpg, these specific DNA-lesions can be detected as an additional outcome.  
Resveratrol was tested in a range of concentrations between 0.1 and 200 µM. UV-radiation 
was used as positive control as it induces double strand breaks in the S-phase (Marti et al., 
2006). Figure 15 shows the results of the Comet Assay performed with resveratrol. 
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Figure 15: The Comet assay was performed with resveratrol in A 431-cells. Incubation time was 1 h at 
37 °C with the addition of catalase [100 U/ml] and FCS [10 %] to the incubation media. DMSO [0.1 %] 
was used as the negative control, UV-radiation was used as the positive control and fpg-treatment was 
also carried out. The means ± SD of 5 replicas are shown. Outliners were excluded using the Nalimov 
test. The significances are related to the negative control (*** = p < 0.001). 
Figure 15 demonstrates that resveratrol does not significantly induce DNA strand breaks, 
even in the highest tested concentration of 200 µM. After incubation with resveratrol, no fpg-
sensitive sites can be observed, therefore no oxidative DNA-lesion was found. 
The positive control, UV-radiation, shows no significant difference between fpg-treatment and 
no enzyme addition. Possibly, UV-exposure caused such a high extend of DNA damage, that 
the additional strand breaks, caused by fpg, did not influence the Comet tail readouts.  As a 
result, the reliability of the graph and the five replicas are weakened. However, the 
possibility, that resveratrol might show an effect at least in the highest tested concentrations 
cannot be excluded. The resveratrol concentrations of 100 and 200 µM show a tendency 
concerning the generation of fpg-sensitive sites, although the effect is not significant. At the 
resveratrol concentration of 200 µM, a tendency in the induction of DNA strand breaks is 
observed. Furthermore, the high standard deviation of the five replicas exacerbates the 
interpretation of the results. Further investigations must be conducted in order to better 
understand the DNA strand breaking potential of resveratrol.  
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Cancer cells were shown to exhibit elevated levels of endogenous copper (Ebadi and 
Swanson, 1988). In previous studies resveratrol was shown to induce DNA double strand 
breaks in the presence of Cu(II) and under pro-oxidative conditions. The presence of 
catalase prevented the copper-catalyzed DNA cleavage effect of resveratrol, indicating the 
need for H2O2 within the reaction (Fukuhara and Miyata, 1998). It was concluded that 
resveratrol mobilizes and reduces endogenous copper, whose re-oxidation generates a 
variety of ROS and induces DNA strand scission (Hadi et al., 2010). 
In order to investigate the DNA strand breaking potential of resveratrol without the influence 
of additional oxidative stress, we added catalase [100 U/ml] to the incubation media. The 
addition of the enzyme avoided the induction of ROS by pro-oxidant H2O2. The use of 
catalase resulted in a reduction of H2O2 in the incubation media and prevented the formation 
of artefacts. According to figure 15, there is no significant difference between samples 
treated with or without fpg, which might be a consequence of the catalase addition reducing 
the oxidative stress and decreasing the number of fpg sensitive sites. It would be interesting 
to perform the Comet assay without the addition of catalase which might lead to a significant 
increase in fpg sensitive sites. 
Leone et al., 2010, used γH2AX-antibodies to detect DNA double strand breaks, and 
reported the occurrence of γH2AX-foci in the human glioblastoma cell line U87-MG after a 
48-hour-incubation with 80µM of resveratrol.  
The histone H2AX belongs to the H2A family organizing eukaryotic DNA into chromatin 
(Bonner et al., 2008). Chromatin modifications are involved in DNA damage recognition and 
repair (Groth et al., 2007). The rapid phosphorylation of H2AX at Ser-139 produces γH2AX 
(Redon et al., 2002). These so called γH2AX foci are seen as quantitative and very sensitive 
markers of DNA double strand breaks (Rothkamm and Lobrich, 2003). The presence of 
γH2AX is a very early indicator of DNA damage as it is detected within minutes after DNA 
damaging irradiation (Sedelnikova et al., 2002). When the repair process is completed, 
γH2AX foci vanish by either de-phosphorylation or removal from chromatin (Bonner et al., 
2008). Resulting from a double strand break in DNA, activated PI3K-like kinases ATM, ATR 
and DNA-PK phosphorylate H2AX and other DNA double strand repair (DDR) proteins 
(Bonner et al., 2008).  
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The detection of DNA double strand breaks using γH2AX as a marker is an indirect method 
of detection, and as such has its intrinsic limitations as it detects activated pathways induced 
for DNA double strand break repair. Even if the strand break is repaired by NHEJ and HRR, 
γH2AX foci may persist in some tumour cells (Kinner et al., 2008). In this context, it was 
shown that resveratrol (≥ 5µM) activates the PI3Ks ATM and/or ATR (Gatz et al., 2008). As 
ATM phosphorylates H2AX, resveratrol might modulate DNA double strand break repair 
pathways and may not be involved in the induction of the initial DNA double strand breaks.  
The study of Leone et al., 2010, demonstrates an effect of 80 µM resveratrol on DNA strand 
break induction. According to our results, resveratrol exposure does not induce significant 
DNA damage but a tendency in the induction of DNA strand breaks around 200 µM is 
observed. However, the experimental setup was different in our study and the question 
arises whether the two distinct results can be compared. The incubation time of 48 hours is 
in contrast to our incubation time of 1 hour. Furthermore, Leone et al., 2010, detected DNA 
double strand breaks with immunohistochemistry staining of nuclear γH2AX foci, while we 
conducted single cell gel electrophoresis (Comet assay).  
It cannot be concluded that our results support the findings of Leone et al., 2010. Further 
experiments are required to reveal the effect of resveratrol on DNA integrity. 
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5.2 Influence of resveratrol on human topoisomerase II 
In order to investigate the effect of resveratrol to inhibit human topoisomerase IIα, we 
conducted the cell-free Decatenation assay. Kinetoplast DNA (kDNA) networks failed to 
migrate into an agarose gel (catenated lane). Upon incubation with topoisomerase II 
decatenated minicircles moved rapidly into the gel due to their small size (decatenated lane). 
Figure 16 shows the results of the Decatenation assay performed with resveratrol. 
 
 
Figure 16: Resveratrol inhibits topoisomerase IIα. Etoposide (Eto) [50 µM] was used as the positive 
control, DMSO [3.3 %] was used as the negative control and kDNA was used as the substrate. 
Decatenation reactions were performed with 1 U of human topoisomerase IIα at 37°C for 1 h of 
incubation. 4-8 replicas were conducted.  
The compound was tested in the concentration range between 1 and 200 µM. As figure 16 
shows, human topoisomerase IIα is inhibited above a concentration of 50 µM resveratrol. 
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To further define the extent of inhibition, the decatenated kDNA lane was quantified and the 
results are shown in Figure 17.  
 
Figure 17: Quantification of the decatenated kDNA after incubation with resveratrol. Etoposide (Eto) 
[50 µM] was used as the positive control and DMSO was used as the negative control. The 
means ± SD of 4-8 replicas are shown. The values were referred to the negative control. Outliners 
were excluded using the Nalimov test. 
According to Figure 17, a 40 % inhibition of the catalytic activity of topoisomerase IIα is 
observed at the highest tested concentration of 200 µM resveratrol. Topoisomerase IIα is not 
inhibited at a concentration below 50 µM of resveratrol. Due to the high error bars, a 
tendency of the inhibitory potential can be observed.  
Leone et al, 2010, showed that resveratrol inhibits the enzyme almost completely at a 
concentration of 80 µM. As the figure of the representative agarose gels shows (Figure 16), 
our results do not contradict the results of Leone et al., 2010. A previous study (Cho et al., 
2000) defined resveratrol as one of the potent chemo-preventive agents with an effective 
inhibition of the catalytic activity of mammalian topoisomerase II. Resveratrol showed a 50% 
inhibition of topoisomerase II at a concentration of 65.72 µM in concordance with a study by 
Jo et al., 2005, showing a dose-dependent inhibition of the enzyme with an IC50 at a 
resveratrol concentration of 78.86 µM.  
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Taken together, these previous results indicate a more potent inhibitory effect of resveratrol 
compared to our observations. However, the mentioned studies did not conduct the 
Decatenation assay as it was performed in our study. It turns out, that the Relaxation assay, 
the Cleavage assay and Decatenation assay might not lead to comparable results. 
In our study, resveratrol was shown to be an inhibitor of topoisomerase IIα above a 
concentration of 50 µM. At the highest tested concentration of 200 µM, resveratrol induces a 
40 % inhibition of topoisomerase IIα. This data indicate that resveratrol inhibits human 
topoisomerase IIα, either as an inhibitor of the catalytic activity or as a topoisomerase II 
poison. In order to investigate whether the substance acts as topoisomerase II poison, the 
ICE-bioassay should be conducted.  
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5.3 Influence of vineatrol
®
30 on human topoisomerase II 
In order to investigate the potential of vineatrol®30 to inhibit human topoisomerase IIα, we 
conducted the Decatenation assay as a cell-free-system. The results are shown in figure 18. 
 
 
Figure 18: Vineatrol
®
30 inhibits human topoisomerase IIα. Etoposide (Eto) [50 µM] was used as the 
positive control, DMSO [3.3 %] was used as the negative control and kDNA was used as the 
substrate. Decatenation reactions were performed with 1 U of human topoisomerase IIα at 37°C for 
1 h of incubation. 3 replicas were conducted. 
As figure 18 shows, the grapevine-shoot extract vineatrol®30 strongly inhibits the enzyme at 
a concentration of 5 µg/ml, whereas no inhibition was observed at 1 µg/ml.  
The Decatenation assay alone cannot distinguish between catalytic inhibitors and 
topoisomerase poisons. In order to investigate the mechanism of vineatrol®30 to inhibit 
human topoisomerase II, the ICE-bioassay was performed. As this assay can directly 
determine the amount of covalent topoisomerase/DNA-complexes, it can be examined 
whether vineatrol®30 acts as a poison generating ternary enzyme/DNA/vineatrol®30-
complexes. Figure 19 shows the results of the ICE-bioassay, performed after the incubation 
with vineatrol®30 in A 431-cells for one hour. 
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Figure 19: The ICE-bioassay was performed with vineatrol
®
30 in A 431-cells. Incubation time was 1 h 
at 37°C with the addition of catalase [100 U/ml] and FCS [10 %] to the incubation media. Etoposide 
(Eto) [50 µM] was used as the positive control and DMSO as the negative control. The experiment 
was performed once. The numbers indicate fractions taken from the gradient.  
As Figure 19 indicates, the positive control Eto shows ternary topoisomerase II/DNA/Eto-
complexes, contained in fraction 4 to 8, and free enzyme within fraction 13 to 20. This 
contrasts with the negative control DMSO that only shows free topoisomerase II. This result 
was expected as Eto is known as a potent topoisomerase II poison (chapter 3.1.4.2).  
Vineatrol®30 was tested within the range of concentrations from 1 to 100 µg/ml and does not 
poison topoisomerase IIα and β. In fraction 4 to 8, no covalent enzyme/DNA-complexes are 
detected, but free enzyme is observed in fraction 13 to 20. Combining the results of the ICE-
bioassay and the Decatenation assay, vineatrol®30 acts as a strong inhibitor of the catalytic 
activity of human topoisomerase IIα. Within intact cells, the extract is not capable to generate 
ternary enzyme/DNA/vineatrol®30-complexes, but interacts with topoisomerase II before the 
DNA-binding-step. 
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According to Wu et al, 2011, the most drug-interacting residues are conserved between 
topoisomerase IIα and β. However, they found a specific drug-contacting residue which is 
different in both isoenzymes, resulting in a polarity change. As there are substances acting 
isoenzyme-specific, it is important to investigate both isoforms of human topoisomerase II. 
With the Decatenation assay as cell-free-system, it cannot be excluded, that the extract 
shows a preference for one topoisomerase isoform within intact cells. The results of the ICE-
bioassay show that vineatrol®30 has the same effect on both human topoisomerase II α and 
β.  
In order to determine the ratio of topoisomerase II covalently bound to DNA and to obtain a 
scaling constant, the DNA content of the samples was measured. The DNA content of the 
negative control DMSO is shown in figure 20.  
 
Figure 20: DNA content of the fractions of the negative control DMSO [0.1 %]. 
The graph indicates that the fraction 6, containing 28 ng/µl, shows the highest DNA content. 
The cells showed no sufficient confluence leading to the measured low DNA content. As a 
result, the reliability of the experiment is weakened as a DNA content above 80 ng/µl would 
be sufficient to differentiate between a strong and a weak poisoning effect. As the experiment 
was performed once, it functions as an initial orientation concerning the effect of the extract 
on topoisomerase II in A 431-cells. At least two repetitions are required to confirm the effect 
of vineatrol®30 on human topoisomerase II.  
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5.4 Influence of resveratrol oligomers on human topoisomerase II 
5.4.1 Hopeaphenol 
As the extract vineatrol®30 showed inhibition of the catalytic activity of human topoisomerase 
IIα, selected resveratrol-oligomers, contained in the extract, were examined. Figure 21 
illustrates the results of the Decatenation assay performed with the resveratrol-tetramer 
hopeaphenol.  
®
 
 
Figure 21: Hopeaphenol inhibits human topoisomerase IIα. Eto [50 µM] was used as the positive 
control and was dissolved in DMSO. Ethanol (EtOH) was used as the negative control and kDNA as 
the substrate. Decatenation reactions were performed with 1 U of human topoisomerase IIα at 37°C 
for 1 h of incubation. 4 replicas were conducted. The 5 µM concentration was tested once to further 
define the threshold of inhibition and no effect. 
According to figure 21, hopeaphenol strongly inhibits the catalytic activity of topoisomerase 
IIα at a concentration above 25 µM. No inhibition is observed at 1 µM of hopeaphenol. The 
quantification of the decatenated kDNA lane is shown in Figure 22. 
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Figure 22: Quantification of the decatenated kDNA after incubation with hopeaphenol. Etoposide (Eto) 
[50 µM] was used as the positive control and DMSO as the negative control. The means ± SD of 4 
replicas are shown. The values were referred to the negative control ethanol. 
For the positive control, the graph (Figure 22) shows a high error bar as the enzyme was 
only inhibited in one replica. In agreement with the gel picture (Figure 21), the results of the 
quantification show a strong topoisomerase IIα inhibition at a concentration above 25 µM. 
10 µM of hopeaphenol resulted in a 30 % inhibition, meaning a relative decatenation effect of 
70 %. The catalytic activity of the enzyme is not inhibited at a hopeaphenol concentration of 
1 µM, whereas 5 µM of hopeaphenol resulted in a 32 % inhibition.  
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5.4.2 r-2-Viniferin 
A further tested constituent of the extract vineatrol®30 was the resveratrol-tetramer r-2-
viniferin. The results of the Decatenation assay are shown in Figure 23. 
 
 
Figure 23: r-2-Viniferin inhibits human topoisomerase IIα. Eto [50 µM] was used as the positive control 
and was dissolved in DMSO. Ethanol (EtOH) was used as the negative and kDNA was used as the 
substrate. Decatenation reactions were performed with 1 U of human topoisomerase IIα at 37°C for 
1 h of incubation. 4 replicas were conducted.  
r-2-Viniferin was tested in a range of concentrations between 0.1 and 25 µM. Figure 23 
indicates that a strong inhibition of the catalytic activity of topoisomerase IIα is induced above 
a concentration of 10 µM r-2-viniferin. At the concentration of 1 µM the enzyme is not 
inhibited.  
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5.4.3 ε-Viniferin 
The resveratrol-dimer ε viniferin, contained in the extract vineatrol®30, was also tested in the 
Decatenation assay and the results are shown in Figure 24. 
 
 
Figure 24: ε-Viniferin inhibits human topoisomerase IIα. Eto [50 µM] was used as the positive control 
and was dissolved in DMSO. Ethanol (EtOH) was used as the negative control and kDNA as the 
substrate. Decatenation reactions were performed with 1 U of human topoisomerase IIα at 37°C for 
1 h of incubation. 4 replicas were conducted.  
ε-Viniferin was tested in the range of concentrations from 1 to 100 µM. Figure 24 
demonstrates that ε-viniferin strongly inhibits topoisomerase IIα at a concentration of 50 µM. 
No inhibition is observed with 10 µM, whereas a almost complete inhibition is shown with 25 
µM of the substance.  
Consistent with the Decatenation assay results of the other substances, the mechanism of 
inhibition cannot be concluded and the ICE bioassay must be performed to examine the 
presence of covalent enzyme/DNA-complexes. Although the extract showed no poisoning, 
the pure constituents might induce the formation of ternary enzyme/DNA/poison-complexes 
in higher concentrations. 
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From the results of the Decatenation assay the question arises, which test substance shows 
the highest potency to inhibit human topoisomerase IIα. Figure 25 illustrates the 
concentrations of the tested constituents of the extract vineatrol®30, as well as the minimal 
inhibition concentration (MIC) to completely inhibit topoisomerase IIα.  
 
Figure 25: Content of the test substances in the extract vineatrol
®
30 (a) and their minimal inhibition 
concentration (MIC) to inhibit human topoisomerase II (b). In the comparison, the MICs were shown in 
µg/ml, and not in the µM-concentrations as in the gel pictures. The vineatrol
®
30 bar shows the 
composition of the extract in relation to the test substances. 
As displayed in figure 25a, ε-viniferin exhibits the highest content in the extract vineatrol®30.  
According to figure 25b, the potency (inverse to MIC) of the pure single compounds is lower 
than the potency of the extract vineatrol®30. However, the three tested constituents may act 
in synergy. Co-incubation experiments could be carried out to assess the synergy effects. 
The extract shows a high potential to inhibit human topoisomerase IIα. The effect is 2-fold 
higher than the effect of the pure constituents. As figure 25b indicates, the effect of ε-
viniferin, r-2-viniferin and hopeaphenol on the inhibition of the enzyme is similar. Comparing 
the gel pictures (Figure 21, 23 and 24), the resveratrol-tetramer r-2-viniferin shows the lowest 
MIC and the therefore the highest potency (Figure 23). 
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6 Conclusion 
In conclusion, it was shown, that resveratrol might not be capable of significantly inducing 
DNA strand breaks, although the tendency is observed with the highest tested concentration 
of 200 µM. No fpg-sensitive-sites were shown (Figure 15). Furthermore, resveratrol inhibits 
the catalytic activity of human topoisomerase IIα at a concentration above 50 µM, in the line 
with Leone et al., 2010 (Figure 16). 
Moreover, it was shown in figure 19 that the grapevine-shoot extract vineatrol®30 does not 
poison both isoforms of human topoisomerase II, but acts as an inhibitor of the catalytic 
activity of the enzyme with the MIC of 5 µg/ml (Figure 18). 
The resveratrol oligomers hopeaphenol, r-2-viniferin and ε-viniferin, contained in the extract 
vineatrol®30, were shown to act as inhibitors of the catalytic activity of human topoisomerase 
IIα. Comparing the gel pictures, r-2-viniferin showed the lowest MIC of 10 µM and the highest 
potency (Figure 23) Hopeaphenol and ε-viniferin completely inhibit topoisomerase IIα above 
a concentration of 25 µM (Figure 21 and 24). The potency of the extract to inhibit 
topoisomerase IIα is 2-fold higher than the potency of the tested constituents (Figure 25) 
suggesting that synergy effects of the constituents occurred. When compared to the 
reference substance resveratrol, resveratrol oligomers showed a stronger potential to inhibit 
topoisomerase II. 
Further examinations are required to confirm that vineatrol®30 does not act as a 
topoisomerase II poison. Whether the extract as well as the pure constituents hopeaphenol, 
r-2-viniferin and ε-viniferin are capable of significantly inducing DNA strand breaks, is also of 
interest. Although the extract might show no poisoning effect on human topoisomerase II, it 
cannot be excluded that one of the pure constituents induces the generation of ternary 
complexes with topoisomerase II/DNA at higher concentrations and the ICE-bioassay should 
be conducted. 
It was shown that the grapevine-shoot extract vineatrol®30 acts as a strong inhibitor of 
topoisomerase II, but might not induce enzyme-mediated DNA-damage by the generation of 
permanent instead of transient DNA double strand breaks, topoisomerase-poisoning, as the 
most effective topoisomerase II-targeting drugs applied in cancer therapy.  
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7 Materials and Methods 
7.1 Cell culture 
7.1.1 Materials 
A431 media 
MEM + 1 % L-glutamine, 10 % or 20 % FCS + 1 % penicillin (10.000 units/ml penicillin-6-
sodium)/streptomycin (10000 μg/ml streptomycin sulphate). 
FCS 
FCS was defrosted slowly, inactivated in the water bath at 56°C for 30 minutes and frozen in 
aliquots at – 20 °C. 
PBS (10x)  
NaCl 1.71 M, KCl 2.7 mM, KH2PO4 1.5 mM, Na2HPO4 8.1 mM, adjusted to pH 7.4. 
Trypsin/EDTA solution  
Trypsin 0.021 mM, EDTA 0.86 mM, PBS (10x) 10 % (v/v), stirred on ice over night, adjusted 
to pH 7.0-7.4, sterile filtrated and frozen in aliquots at – 20 °C. 
7.1.2 Sterile working procedure 
The media, PBS and trypsin/EDTA were pre-warmed in a water bath at 37 C and the airflow 
in the hood was stabilized for about 10 minutes. The required pipettes were flamed and an 
aspirating pipette was attached to vacuum. All the materials including tubes and flasks were 
cleaned with 70 % ethanol. The hands were covered with gloves and cleaned with ethanol. 
7.1.3 Mycoplasma test 
A sterile microscope slide was transferred into a dish filled with culture media. The cells were 
trypsinized and 3-4 drops of the cell suspension were applied to the slide surface. After 24-
72 hours, when a cell confluence of 50-70 % was observed, the culture media was replaced 
by – 20 °C cold methanol. In order to fix the cells, the slide was transferred into a Coplin 
chamber with – 20 °C-cold methanol for at least 30 minutes. Then, three drops of 4',6-
diamidino-2-phenylindole (DAPI)/SR 101 staining-solution [1 µg/ml] were applied to the slide. 
The detection was performed using fluorescence microscopy with an excitation wave length 
of 340 nm and an emission wave length of 488 nm. The experiments were performed 
exclusively with mycoplasma-free cells (Lindl and Gstraunthaler, 2008).                     
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7.1.4 Cell line A 431 
The epithelial-like A 431 cell line was established from the solid tumour of an 85-year-old 
woman. When adherence is achieved, A 431 cells grow in monolayers with a doubling time 
of about 80-100 hours. Therefore, cell passaging should be constantly performed depending 
on the cell confluence (DSMZ, Braunschweig). 
7.1.5 Cell culture conditions 
A 431 cells were cultured in MEM containing 1 % L-glutamine, 10 % FCS as well as 1 % P/S. 
The cells were cultured in monolayers in T flasks at the incubator conditions of 37 °C, 5 % 
CO2 and 95 % relative humidity.  
7.1.6 Changing media 
With increasing confluence, the conditions change constantly in a batch culture in terms of 
raising metabolites concentration as well as decreasing nutrients. These continuous 
variations influence not only the pH-value, but also the redox-state of the cells. Cell lines 
growing as monolayers in dishes or T flasks, require the continuous change of the media for 
their growth and viability (Lindl and Gstraunthaler, 2008). 
7.1.7 Passaging cells  
It was confirmed under the microscope that the cells in the T-flask showed a confluence of 
90 % - 100 %. The cells were washed with 10 mL of PBS and the buffer was aspirated from 
the T-flask. Then, 2.5 ml of trypsin/EDTA was added and the cells were incubated at 37 °C 
for 8 minutes. The T-flask was removed from the incubator and the side of the T-flask was 
tapped on the hand for several times. During this procedure, it was checked if cell clusters 
were dispersed. In order to stop the trypsin reaction, 10 ml of culture media was added to the 
T flask and the cells were carefully re-suspended. Depending on the experimental setup, a 
certain volume of the cell suspension was transferred into a T-flask filled with media and put 
back into the incubator (Lindl and Gstraunthaler, 2008). 
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7.1.8 Counting cells and seeding 
The density of initially inoculated cells influences the growth rate of adherent growing cells. It 
has to be found a balance between too confluent cells inhibiting growth and too low cell 
density slowing growth.  The cell number was determined using the Neubauer cell counting 
chamber which is a precision instrument. The grid of a cell counting chamber is shown in 
Figure 26. 
 
Figure 26: Illustration of the Neubauer cell counting chamber. a) The grid of the cell counting chamber 
is depicted. b) In this picture dead cells are shown in white, viable cells are illustrated in blue. The red 
cells are not counted (modified according to Lindl and Gstraunthaler, 2008). 
After trypsination, the cell suspension was stained with trypan blue (dilution 1:10). By 
applying a drop of the cell suspension, a specified volume was drawn into the grid by 
capillary forces. The cells in the four quadrants were counted. The cell number per milliliter of 
the cell suspension was calculated by multiplication of the average cell number in each 
quadrant with the dilution factor as well as with the volume factor 104. Depending on the 
designated cell number, a certain volume was inoculated into the media and equitable 
applied to the dishes (Lindl and Gstraunthaler, 2008). 
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7.1.9 Determination of the cell viability 
In order to differentiate vital from dead cells, the trypan blue test was used. As an acidic dye 
trypan blue can bind to proteins in its anionic state. The principle of this test lies in the fact 
that the dye does not accumulate in the intracellular of vital cells as it is transported out of the 
cell. By contrast, dead cells are stained because their metabolism is disturbed. 
Viability means the ratio of vital cells to the total cell number and is calculated with the 
following formula: 
             
               
                              
      
(Lindl and Gstraunthaler, 2008) 
7.1.10 Defrosting cells 
The A 431 cell stocks stored in a cryo tube at – 80 °C were quickly transferred into a water 
bath at 37 °C. The cells were defrosted in the water bath and immediately transferred into 
10 ml pre-warmed culture media containing 20 % of FCS. Then, the cell suspension was 
centrifuged at 250 x g at RT for five minutes. After discarding the supernatant, the cell pellet 
was re-suspended in 5 ml of the media and transferred to a T-flask (25 cm2). Another 5 ml of 
culture media was added. The cells were not touched during the following twelve hours. After 
two passages, the FCS-concentration was decreased to 10 %                                      
(Lindl and Gstraunthaler, 2008). 
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7.2 Test substances 
The grapevine-shoot extract vineatrol®30 and the pure constituents hopeaphenol, ε-viniferin 
as well as r-2-viniferin were provided by Prof. Pablo Steinberg from the Institute of Food 
Toxicology and Analytical Chemistry of the Veterinary University Hannover. Resveratrol was 
purchased from Sigma. The molecular weight of the test substances is summarized in 
Table 5. 
Table 5: Molecular weight of the test substances. 
test substance molecular weight [g/mol] 
  
vineatrol®30 Extract 
ε-viniferin 454.5 
r-2-viniferin (visitin A) 1 890.8 
hopeaphenol 906.9 
trans-resveratrol 228.25 
 
Hopeaphenol, ε-viniferin and r-2-viniferin were dissolved in ethanol. Vineatrol®30 and 
resveratrol were dissolved in DMSO. The stock solutions were stored at – 80 °C.  
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7.4 Single cell gel electrophoresis: Comet assay  
In the Comet assay, established by Ostling and Johanson, 1984, the cells are embedded in 
agarose on a microscope slide. The cells form a cavity in the gel and most of the 
biomolecules diffuse through the agarose gel into the lysis buffer. Only DNA stays in the 
cavity due to its high molecular weight.  When applying an electric field, DNA fragments 
migrate towards the anode, is released from the cavity and forms a “tail”, whereas intact DNA 
shows no or less migration. Strand breaks enhance the migration of DNA towards the anode 
due to the changes in DNA topology. Therefore, strand breaks can be quantified according to 
the tail intensity. Figure 27 shows the experimental setup of the Comet assay. 
Because the Comet assay according to Ostling and Johanson, 1984, is performed under 
neutral conditions only DNA double strand breaks can be detected. Singh et al., 1988, 
developed the Comet assay under alkaline conditions.  Due to the alkaline conditions, not 
only cellular RNA disturbing the quantification is degraded, but also the DNA double strands 
are separated. Therefore, both single- and double-stranded DNA-breaks as well as other 
alkali-sensitive-sites can be detected. Additional treatment with specific enzymes can detect 
common DNA lesions.  
 
Figure 27: Experimental Setup of the Comet assay.  
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Incubation 
A 431 cells were seeded at a density of 3x 105 cells/dish in culture media for 48 hours. At a 
confluence of 50-60 %, the cells were exposed to resveratrol [0.2-200 µM[ for one hour. 
DMSO [0.1 %] was used as solvent. In order to compensate H2O2 generation, catalase 
[100 U/ml] was added. UV-light exposure for two minutes was used as the positive control 
whereas DMSO [0.1 %] was used as the negative control. 
Preparation of the slides 
Two slides for each incubated dish were prepared meaning one slide additionally for the fpg-
treatment. 
Melted 0.8 % normal-melting agarose (NMA) (40 µl) was coated on the matted side of the 
slide. After drying, the slides were coated for a second time in order to achieve a better grip 
for the pads. The pads consisting of NMA (65 µl) were applied to the coated slides and 
coverslipped free from air bubbles. The slides were dried on an ice-cold surface to allow 
solidification of agarose for at least 30 minutes and stored in a wet slide box at 4 °C. 
Preparation of the cells 
After incubation, the media was discarded and the cells were washed twice with pre-warmed 
PBS (2x 2 ml). The cells were trypsinised at 37 °C for eight minutes. The trypsin reaction was 
stopped with FCS-containing culture media (0.5 ml) and the cell suspension was transferred 
into ice-cold tubes. In order to collect all cells, the dish surface was rinsed with culture media 
(0.5 ml) and pooled with the first fraction. 
Viability test 
The cell suspension was stained with trypan blue (1:2) in order to maintain the ratio of dead 
to vital cells. For the exclusion of cytotoxic effects, the cell viability should be higher than 
80 %. 
Embedding of cells in the agarose pads 
The cell suspension was separated into four aliquots containing 30,000 cells each and 
transferred into a tube. After centrifugation at 2,000 rpm at 4 °C for ten minutes the 
supernatant was discarded. 
For blind testing, the prepared cover slides were encoded.  The cells were re-suspended in 
0.8 % low-melting agarose (LMA) (65 µl), applied to the NMA-pads and covered with a cover 
slip free from air bubbles. The slides were dried on an ice-cold surface for at least 15 
minutes. 
  
52 
 
Cell lysis 
Cover slips were removed and the slides were put in a Coplin chamber containing cold lysis 
buffer (89 ml of lysis stock solution:  NaCl 2.5 M, EDTA 100 mM, tris 100 mM , N-
lauroylsarcosyl sodium salt 1 % (w/v), pH 10; 10 ml of DMSO, 1 ml of triton X-100). The cells 
were lysed at 4 °C for at least one hour. DNA unfolding occurred during the lysis process. 
Fpg-treatment 
Formamidopyrimidine-DNA-glycosylase (fpg) was used to detect the presence of FapyAde 
and FapyGua, which are common DNA lesions caused under oxidative conditions. The 
slides were washed with ice- cold 1x fpg-enzyme buffer (10x stock solution: HEPES 400 mM, 
KCl 1 M, EDTA 5 mM, BSA 2 g/l, pH 8) at 4 °C for 3x5 minutes. During the last washing step, 
10 µl aliquots of fpg-enzyme were defrosted on ice. Then the aliquots were diluted (1:30) 
using ice-cold 1x fpg-enzyme buffer. The slides were covered with either 50 µl of the 
enzyme-buffer or 50 µl of the enzyme and incubated in a wet chamber at 37 °C for 30 
minutes. 
Alkalinization and electrophoresis 
After removing the cover slips the slides were applied to an ice-cold electrophoresis 
chamber. The chamber was filled with electrophoresis buffer (NaOH 10 M, 3 % (v/v), EDTA 
200 mM 0.5 % (v/v)). The slides were alkalized in the dark for 20 minutes. During this 
alkalization step, DNA unwinding occurred. The required amperage was adjusted by addition 
or removal of electrophoresis buffer. Then electrophoresis ran at 25 V and 300 mA in the 
dark for 20 minutes. 
Neutralization 
In order to confer DNA in its double stranded state, a washing step with neutralization buffer 
(tris/HCl 400 mM, pH 7.5) was performed. With neutralization buffer also alkali and 
detergents which could interfere with ethidium bromide were removed. The slides were 
washed with neutralization buffer at 4 °C for 3x5 minutes. 
DNA staining 
Ethidium bromide solution ready to use (36 µl) (250x stock-solution: 1 µg/ml ethidium 
bromide in H2O) was applied to the slides and covered with a cover slip. 
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Analysis 
The analysis was performed using a fluorescence microscope with a mercury vapour lamp 
as light source. Ethium bromide was excited at a wave length of 512 nm using a connected 
CY-3 filter resulting in an emission at a wave length of 590 nm. The image was taken with a 
CCD camera and analysed with the software Comet Assay IV-System (Perspective 
Instruments). For each gel pad 50 non-overlapping cells were analysed and the mean value 
of the tail intensities was calculated. After analyzing all slides, the encoding was abolished. 
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7.5 Inhibition of the catalytic activity of topoisomerase II α: 
Decatenation assay 
With this cell-free assay, inhibition of catalytic activity of topoisomerase II can be examined. 
The catenated DNA substrate was prepared from the kinetoplast of the insect trypanosome 
Crithidia fasciculata.  Kinetoplast DNA (kDNA) is an aggregate of connected DNA mini-
circles (mostly 2.5 kb) generating large networks of high molecular weight. Consequently, 
these networks fail to migrate into an agarose gel. Upon incubation with topoisomerase II, 
which engages DNA in a double stranded breaking and reunion cycle, DNA minicircles are 
released (decatenated).  The decatenated minicircles move rapidly into the gel owing to their 
small size (Figure 28). 
a)    
 
b) 
 
Figure 28: Experimental setup of the Decatenation assay. a) Release of minicircles from kDNA 
catalyzed by topoisomerase II b) Catenated DNA 
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Table 6: Pipette scheme of the Decatenation assay. 
Solution kDNA [µl] 
kDNA + topo IIα + 
inhibitor [µl] 
   
H2O bidest. 18.95 17.40 
KCl 1 M 3.6 3.6 
Saltmix II (MgCl2 50 mM, DTT 
5 mM EDTA 5 mM, ATP 10 
mM, BSA 0.3 mg/ml 
3 3 
Tris/HCl 500 mM, pH 7.9. 3 3 
kDNA 250 ng/µl 1 1 
Substance or control  1 
Topoisomerase IIα [1 U] (1:50 
in dilution buffer, tris/HCl 50 mM 
(pH 7.5), NaCl 400 mM, DTT 
1 mM, glycerol 50 % (v/v) 
1 1 
Proteinase K (1 mg/ml in 
10 % (w/v) SDS-solution) 
3 3 
Loading dye 
(Bromine phenole blue 
0.25% (w/v), glycerol 30% (v/v)) 
5 5 
 
Incubation and detection  
The reaction mix was pipetteted according to table 6 and incubated at 37 °C for 60 minutes 
Etoposide (50 or 100 µM) was used as the positive control and the specific solvent, DMSO or 
ethanol (3.3 %) was used as the negative control. 
As the enzyme might influence the migration of the DNA through the gel, it was denatured by 
proteinase K. Incubation with proteinase K was performed at 37°C for 30 minutes. Loading 
dye was added and 17 µl of the samples each were applied to the gel (agarose 1 % (v/v) in 
1x TAE buffer (TAE buffer 50x: tris 2 M, acetic acid 5.71% (v/v), EDTA 0,5 M (pH 8.0) 10%, 
pH 8.5).  
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Electrophoresis was performed at 60 V for three hours in 1x TAE buffer. The gel was stained 
with ethidium bromide (1 µg/ml in H2O) for 20 minutes and washed in H2O for five minutes. 
The lanes were detected using LAS 4000 at a fluorescence wavelength of 560 nm. 
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7.6 ICE (in vivo complex of enzyme to DNA)-bioassay 
Antibodies 
Primary antibody  
Anti-topoisomerase IIα (rabbit, Santa Cruz): 1:333 in blocking buffer 
Anti-topoisomerase IIβ (rabbit, Santa Cruz): 1:333 in blocking buffer 
Secondary antibody 
Anti-rabbit HRP-IgG-conjugated (Santa Cruz): 1:2000 in blocking buffer 
According to its name, this assay can detect covalent complexes of DNA and 
topoisomerases. Therefore, topoisomerase inhibitors can be examined concerning their 
mechanism of action. As only topoisomerase poisons can stabilize covalent enzyme/DNA-
complexes they can be distinguished from catalytic inhibitors. 
The principle of this assay lies in a separation according to densities using a CsCl gradient. 
Covalent DNA-topoisomerase-complexes gravitate during ultracentrifugation. By contrast, 
non-covalent protein-DNA-interactions dissociate in the density gradient. Free topoisomerase 
can be detected in the upper part of the centrifugation tube. Fractions of the gradient are 
taken and plotted on nitrocellulose. Topoisomerase II α and IIβ can be detected by the use of 
specific antibodies (Figure 29). 
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Figure 29: Experimental setup of the ICE-bioassay. 
 
Sample preparation  
A 431 cells were seeded at a density of 3x 106 cells/dish in culture media for 72 hours. At a 
confluence of 80-90 %, the cells were exposed to vineatrol®30 [0.1 µM-250 µM] for one hour. 
In order to compensate H2O2 generation, catalase [100 U/ml] was added. 
Cells were washed with 2x4 ml 1x PBS each and lysed by the addition of 6 ml of lysis buffer 
(sarcosinate 1 % (w/v) in TE-buffer). Cells were harvested by abrading and transferred into 
15 ml tubes. DNA was sheared using an insulin syringe and 4 ml of the cell lysate was 
layered onto a CsCl gradient in polyallomer tubes.  
Generation of the CsCl gradient and ultracentrifugation 
Each of the polyallomer tubes was layered carefully with solution A-D (2ml each) with a 
decreasing density from the bottom to the top.  
A: 1850 μl CsCl solution (120 g CsCl in 70 ml TE-buffer) + 150 μl TE buffer (tris/HCl 10 mM, 
EDTA 1 mM, pH 8) 
B: 1600 μl CsCl solution + 400 μl TE buffer  
C: 1100 μl CsCl solution + 900 μl TE buffer  
D: 900 μl CsCl solution + 1100 μl TE buffer) 
Centrifugation
(CsCl-gradient)
Incubation
and cell lysis
Free Topoisomerase
DNA / Topoisomerase 
Intermediate
Slot-Blot Transfer and
Immunodetection
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The solution was covered with mineral oil in order to tare the ultracentrifuge and to exclude 
oxygen. Ultracentrifugation was performed using the swing rotor TST 41.14 at 23,000 rpm 
(100,000 x g) and 20 °C for at least 22 hours. 
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Fractionation and blotting 
a) 
 
 
 
 
b)  
 
 
 
 
 
 
 
Figure 30: a) Slot blot apparatus b) Assembly of the slot blot apparatus.  
 
The nitrocellulose membrane as well as the Whatman papers (2 for each membrane) were 
equilibrated in 25 mM phosphate buffer (phosphate buffer 1 M: Na2HPO4 1 M, NaH2PO4 1 M, 
mixed 1:1) at 4°C. 
The gradient was fractionated from the bottom of the polyallomer tube using insulin syringes.  
20 fractions (300 µl each) were gathered and vortexed with 25 mM phosphate buffer (300 µl).  
The cell components of the sample solution (200 µl) were blotted on a nitrocellulose 
membrane using the slot-blot-system (Figure 30). 
Blocking and incubation with primary antibody  
The membranes were equilibrated in 1x TBST buffer (10x TBST buffer: tris 200 mM , NaCl 
1.37 M,tween-20 1% (v/v), pH 7.5) for ten minutes.  Unspecific binding sites of the antibody 
were blocked (blocking buffer: milk powder 5 % (w/v) in 1x TBST) at RT for three hours. 
Incubation with topoisomerase IIα or β antibody (1:333 in blocking buffer) was performed at 
4 °C over night. 
  
Platform for sample applying 
 Transfer membrane 
 
 
 
 
2 Whatman papers 
Silicone ring 
Lateral closing 
Vacuum filter unit 
Silicone blinding 
Basis unit 
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Incubation with secondary antibody and detection 
The membranes were washed in 1x TBST for 3x 5 minutes to remove non-bound antibody. 
Incubation with HRP-conjugated anti-rabbit antibody was performed at RT for 2 hours. The 
membranes were washed (3x 5 minutes). Chemiluminescence reaction was started by 
LumiGlo and detected using LAS-3000 (Image Reader, Fujifilm). 
Determination of the DNA content  
The DNA concentration was measured using nanodrop®-spectrophotometer at a wavelength 
of 260 nm. Due to its high density DNA is expected in the initial fractions. As blank 2 µl of 
H2O were used. The detection was performed using ND 1000 V 3.2.1 software. 
Analysis 
The DNA-rich fractions of the negative control DMSO are taken as reference. 
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7.7 Chemicals 
Table 7: List of chemicals. 
Substance Manufacturer 
Adenosine triphosphate ( ATP) 
Acetic acid 
Agarose 
Bovine serum albumine (BSA) 
Bromine phenole blue  
Catalase 
Cesium chloride 
4',6-diamidino-2-phenylindole (DAPI)/SR 101  
1,4-Dithiothreitol (DTT) 
Dimethyl sulfoxide (DMSO)  
Ethylene diamine tetraacetic acid (EDTA) 
Ethanol 
Ethidium bromide 
Etoposide 
Fetal calf serum (FCS)  
Glycerol 
HEPES 
Hydrochloric acid 
Kinetoplast DNA (kDNA ) 
lauroylsarcosyl sodium salt  
L-glutamine (L-Glu) 
LumiGLO  
Methanol 
Sigma 
Roth 
Invitrogen 
Roth 
Sigma 
Sigma 
Roth 
Partec 
Fluka 
Roth 
Roth 
Roth 
Roth 
Sigma 
Invitrogen 
Roth 
Roth 
Merck 
Topogen 
Roth 
Sigma 
Santa Cruz 
Merck 
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Magnesium chloride 
Mineral oil  
Minimum essential media (MEM) 
Milk powder  
Phosphate buffered saline (PBS) 
Penicillin/Streptomycin ( P/S) 
Proteinase K 
Potassium chloride 
Potassium hydrogen phosphate 
Sodium dodecyl sulfate (SDS) 
Sodium chloride 
di-sodium hydrogen phosphate 
Sodium hydroxide 
Tris 
Triton X-100  
Trypan blue 
Trypsin 
Tween-20 
 
 
Roth 
Sigma 
Invitrogen 
Roth 
Gibco 
Sigma 
Sigma 
Roth 
Roth 
Roth 
Roth 
Roth 
Roth 
Roth 
Sigma 
Sigma 
Invitrogen 
Sigma 
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7.8 Materials 
Table 8: List of materials. 
Material Manufacturer 
Cover slips 
Eppendorf tubes 
Glass pipettes  
Culture flasks 
Pipette  (blue, yellow, bright)  
Pipette 5ml 
Pasteur pipettes   
Dishes (d= 5 or 20 cm)   
Tubes (v=13, 15, 50 ml) 
Whatman nitrocellulose transfer membrane 
Whatman papers 
Cell abrading scraper, 25 cm,  
Menzelgläser 
Sarstedt AG, Co 
VWR 
Sarstedt AG, Co 
Sarstedt AG, Co 
VWR 
Carl Roth GmbH, Co. KG 
Sarstedt AG, Co 
Sarstedt AG, Co  
Pall Life Sciences  
Whatman Inc. 
Sarstedt AG, Co 
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7.9 Equipment 
Table 9: List of equipment.       
Equipment Manufacturer 
Autoclave Systec DX-150 Systec GmbH 
Bio freezer VipTM Series Sanyo 
Burner Fuego Basi WLD-TEC 
Incubator Heracell 240 i, CO2 Incubator Thermo Fisher Scientific 
Ice machine MF 46 Scotsman Frimont 
Gel documentation machine LAS-4000 Luminescent Image Analyser, Fujifilm, 
software: Image Reader LAS 4000; detection: 
Multi Gauge V3.2 
Gel electrophoresis Mini-PROTEAN® Tetra System, Bio Rad Modell 
45-2010-i, Peqlab Biotechnology GmbH 
Fridge/freezer Liebherr Comfort (4 °C, -20 ° C), Liebherr 
Magnetic stirrer IKA® RCT basic, safety control, IKA 
Microscope Inversmikroskop Axiovert 40C, Zeiss 
Neubauer cell counting chamber Marienfeld 
pH-meter Mettler Toledo Seven Easy, Mettler,Toledo 
Pipettes, multipipettes Eppendorf Research P 10 –P 5000, Eppendorf 
Pipettetus accu Hirschmann Laborgeräte 
Power station electrophoresis Power Supply EV231, PeQlab 
Vacuum pump Laboport®, IBS Integra biosciences 
Over head shaker Roto-Shake-Genie, Scientific Industries 
Spectral photometer Nanodrop 2000c Spectrophotometer, Peqlab 
Biotechnology GmbH 
Sterile bench Hera Safe KS 18Thermo Fischer Scientific 
Thermocycler MJ Research PTC-200, Peltier Thermal Cycler 
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Drying chamber Binder, ATP lineTM ED (E2), Binder GmbH 
Vortex Bio Vortex V1, Peqlab Biotechnologies Vortex 
Genie 2 Scientific Industries 
   
Scales Scale New Classic MF, ML204/01 Mettler Toledo  
Scale Micro, Sartorius AG 
Scale New Classic MF, ML6001/01Mikro 200, 
Mettler Toledo GD 100, Grant 
Water bath GD 100, Grant 
Centrifuges Table centrifuge, Mikro 220R, Hettich Zentrifugen 
Table centrifuge, Mikro 200, Hettich Zentrifugen 
Table centrifuge, Galaxy MiniStar, VWR 
Ultra centrifuge, Optima L-100XP, Beckmann 
Coulter 
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9.1 Abstract 
Resveratrol (3, 4`, 5-trihydroxystilbene) has shown to exhibit beneficial effects in the 
prevention of different stages of carcinogenesis. The grapevine-shoot extract vineatrol®30, 
admitted as a dietary supplement, contains a high amount of resveratrol as well as 
resveratrol oligomers and –polymers. Recently, it was shown that resveratrol induces DNA 
double strand breaks and inhibits the catalytic activity of human topoisomerase IIα (Leone et 
al., 2010).  
The aim of the current study was firstly to confirm the effect of resveratrol on human 
topoisomerase IIα and DNA integrity. Secondly, it should be determined whether the extract 
vineatrol®30 acts as an inhibitor of the catalytic activity of human topoisomerase II, or as a 
poison by the generation of ternary complexes with the enzyme and DNA. Thirdly, the 
bioactive constituents in vineatrol®30 concerning the effect on topoisomerase II should be 
identified.  
Using the Comet assay, it was shown that resveratrol exposure (0.1-200 µM) for one hour 
might not be capable of inducing DNA strand breaks in the human vulva carcinoma cell line 
A 431 although the tendency is observed with the highest tested concentration. Furthermore, 
resveratrol inhibits the catalytic activity of human topoisomerase IIα with a minimal inhibition 
concentration (MIC) of 50 µM as tested with the cell-free Decatenation assay.  
The extract vineatrol®30 was shown to inhibit the catalytic activity of topoisomerase IIα with a 
MIC of 5 µg/ml. Selected extract-constituents (hopeaphenol, r-2-viniferin and ε-viniferin) 
inhibited the catalytic activity of the enzyme within the range of MICs between 10 and 25 µM 
with r-2-viniferin as the most potent test-substance in a cell-free system. Furthermore, it was 
concluded that vineatrol®30 does not poison human topoisomerase IIα and IIβ in A 431 cells 
as no ternary enzyme/DNA/vineatrol®30-complexes were detected using the ICE-bioassay.  
In conclusion, it was shown that resveratrol might not be capable of significantly inducing 
DNA strand breaks in the tested concentrations, but inhibits the catalytic activity of human 
topoisomerase IIα. The grapevine-shoot extract vineatrol®30 acts as strong inhibitor of the 
enzyme, but might not induce enzyme-mediated DNA-damage by the generation of 
permanent instead of transient DNA double strand breaks, topoisomerase-poisoning, as 
performed by the most effective topoisomerase II-targeting drugs applied for cancer therapy.  
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9.2 Abstract German 
Resveratrol (3, 4`, 5-Trihydroxystilben) wirkt präventiv in unterschiedlichen Stadien der 
Karzinogenese. Der Weinrebensprösslingsextrakt Vineatrol®30, der bereits als 
Nahrungsergänzungsmittel zugelassen ist, besteht zu einem Großteil aus Resveratrol sowie 
Resveratrol Oligo-und Polymeren. In einer aktuellen Studie wurde gezeigt, dass Resveratrol 
sowohl DNA-Doppelstrangbrüche induziert, als auch die katalytische Aktivität der humanen 
Topoisomerase IIα hemmt (Leone et al., 2010).  
Ziel der vorliegenden Arbeit war es, die Wirkung von Resveratrol auf humane 
Topoisomerase IIα  sowie auf die Integrität der DNA zu bestätigen. Außerdem sollte 
untersucht werden, ob der Extrakt Vineatrol®30 die katalytische Aktivität der humanen 
Topoisomerase IIα hemmt, oder ob dieser die Bildung von ternären Komplexen mit dem 
Enzym und der DNA induziert, und somit als Topoisomerase-Gift wirkt. Des Weiteren sollten 
die bioaktiven Inhaltsstoffe bezüglich des Effekts auf Topoisomerase II in Vineatrol®30 
identifiziert werden. 
Mittels Comet Assay konnte gezeigt werden, dass Resveratrol in den Konzentrationen von 
0,1 bis 200 µM mit einer Inkubationszeit von einer Stunde keine DNA-Strangbrüche in der 
humanen Vulvakarzinomzelllinie A-431 induziert, obwohl die Tendenz dazu in der höchsten 
Testkonzentration feststellbar war. Des Weiteren hemmte Resveratrol die katalytische 
Aktivität der humanen Topoisomerase IIα mit einer minimalen Inhibierungskonzentration 
(MIC) von 50 µM, wie mit dem zellfreien Dekatenierungsassay gezeigt werden konnte. 
Der Extrakt Vineatrol®30  hemmte die katalytische Aktivität der humanen Topoisomerase IIα 
mit einer MIC von 5 µg/ml. Ausgewählte Inhaltsstoffe des Extrakts (Hopeaphenol, r-2-
Viniferin und ε-Viniferin) hemmten die katalytische Aktivität des Enzyms in einem MIC-
Bereich von 10 bis 25 µM, wobei sich r-2-Viniferin als die potenteste Testsubstanz in einem 
zellfreien System herausstellte. Außerdem wirkt Vineatrol®30  wohl nicht als Topoisomerase 
II-Gift in A-431-Zellen, da keine ternären Enzym/DNA/ Vineatrol®30 - Komplexe mittels ICE-
Bioassays nachgewiesen werden konnten. 
Abschließend konnte gezeigt werden, dass Resveratrol wohl keine signifikanten DNA- 
Strangbrüche in den getesteten Konzentrationen induziert, aber die die katalytische Aktivität 
der humanen Topoisomerase IIα durch diese Substanz gehemmt wird. Der 
Weinrebensprösslingsextrakt Vineatrol®30 wirkt als starker Inhibitor des Enzyms, obwohl 
keine enzymvermittelte DNA-Schädigung, als Folge der Bildung permanenter anstatt 
transienter DNA-Doppelstrangbrüche, der Topoisomerase-Giftung, festgestellt werden 
konnte, wie es bei den stärksten Topoisomerase II-Krebstherapeutika der Fall ist.   
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